Loading...
•
Jun 30, 2020
Insmed Q2 2020 Earnings Report
Insmed reported financial results for the second quarter ended June 30, 2020, and provided a business update.
Key Takeaways
Insmed reported strong sequential growth in ARIKAYCE U.S. sales and continued to advance brensocatib, which received Breakthrough Therapy Designation from the FDA. The company also received a positive CHMP opinion for ARIKAYCE in the European Union.
ARIKAYCE U.S. sales showed strong sequential growth from the first quarter.
ARIKAYCE was included in the new international treatment guidelines.
A positive CHMP opinion in European Union was received to advance global growth.
Brensocatib Received FDA Breakthrough Therapy Designation in Patients with Non-Cystic Fibrosis Bronchiectasis
Insmed
Insmed
Forward Guidance
Insmed plans to continue investing in key activities in 2020.